LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

To investigate the activating effect of local lesion low-dose radiotherapy (2Gy) on the tumor immune microenvironment, and the efficacy, safety, and feasibility of its combination with pembrolizumab and standard therapy in patients with advanced pancreatic cancer. Concurrently, to preliminarily establish an efficacy prediction model for the early identification of patient populations who would benefit from the treatment, thereby providing a theoretical foundation for the implementation of precision medicine.

Trial Details

NCT ID
NCT07312422
Phase
PHASE1 / PHASE2
Sponsor
Zhejiang Provincial People's Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Low-dose Radiotherapy
  • Pucotenlimab
  • AG regimen
  • FOLFIRINOX regimen
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Age ≥ 18 years, regardless of gender;
  • ECOG score of 0 to 1;
  • Patients with histologically or cytologically confirmed pancreatic malignancy;
  • No prior treatment with PD-1 or PD-L1 inhibitors;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →